Page:United States Statutes at Large Volume 111 Part 3.djvu/230

From Wikisource
Jump to navigation Jump to search
This page needs to be proofread.


Ill STAT. 2318 PUBLIC LAW 105-115—NOV. 21, 1997 a meeting for the purpose of reaching agreement on the design and size of bioavailability and bioequivalence studies needed for approval of such application. The sponsor or applicant shall provide information necessary for discussion and agreement on the design and size of such studies. Minutes of any such meeting shall be prepared by the Secretary and made available to the sponsor or applicant. "(C) Any agreement regarding the parameters of design and size of bioavailability and bioequivalence studies of a drug under this paragraph that is reached between the Secretary and a sponsor or applicant shall be reduced to writing and made part of the administrative record by the Secretary. Such agreement shall not be chsinged after the testing begins, except— "(i) with the written agreement of the sponsor or applicant; or "(ii) pursuant to a decision, made in accordance with subparagraph (D) by the director of the reviewing division, that a substantial scientific issue essential to determining the safety or effectiveness of the drug has been identified after the testing has begun. "(D) A decision under subparagraph (C)(ii) by the director shall be in writing and the Secretary shall provide to the sponsor or applicant an opportunity for a meeting at which the director and the gponsor or applicant will be present and at which the director will document the scientific issue involved. "(E) The written decisions of the reviewing division shall be binding upon, and may not directly or indirectly be changed by, the field or compliance office personnel unless such field or compliance office personnel demonstrate to the reviewing division why such decision should be modified. "(F) No action by the reviewing division may be delayed because of the unavailability of information from or action by field personnel unless the reviewing division determines that a delay is necessary to assure the marketing of a safe and effective drug. "(G) For purposes of this paragraph, the reviewing division is the division responsible for the review of an application for approval of a drug under this subsection (including scientific matters, chemistry, manufacturing, and controls).". (2) CONFORMING AMENDMENTS.— Section 505(j) (21 U.S.C. 355(j)), as amended by paragraph (1), is further amended— (A) in paragraph (2)(A)(i), by striking "(6)" and inserting "(7)"; (B) in paragraph (4) (as redesignated in paragraph (D), by striking "(4)" and inserting "(5)"; (C) in paragraph (4)(I) (as redesignated in paragraph (D), by striking "(5)" and inserting "(6)"; and (D) in paragraph (7)(C) (as redesignated in paragraph (1)), by striking "(5)" each place it occurs and inserting "(6)". SEC. 120. SCIENTIFIC ADVISORY PANELS. Section 505 (21 U.S.C. 355) is amended by adding at the end the following: "(n)(l) For the purpose of providing expert scientific advice and recommendations to the Secretary regarding a clinical investigation of a drug or the approval for marketing of a drug under section 505 or section 351 of the Public Health Service Act, the